Curriculum Vitae

CURRICULUM VITAE

Joseph P. Hanna M.D.

BUSINESS ADDRESS: Department of Neurology MetroHealth Medical Center 2500 MetroHealth Drive

Cleveland, OH 44109-1998

HOME ADDRESS: 9292 Oxford Trail Brecksville, OH 44141 (216) 210-8718

APPOINTMENTS:7/93 to 12/94 Clinical Associate, Department of Neurology,

Cleveland Clinic Foundation

4/96 to 6/01 Senior Clinical Instructor, Department of Neurology,Case Western Reserve University

7/01 to 7/07 Assistant Professor, Department of Neurology,Case Western Reserve University

7/07 to Present Associate Professor, Department of Neurology,Case Western Reserve University

EMPLOYMENT HISTORY:1. Interim Chief Operating Officer, MetroHealth System, January 2013

through June 2013.

2. Executive Director, Specialty Care Patient Care Unit, MetroHealth Medical Center, February 2009 to January 2015

3. Medical Director, The Stroke Center at MetroHealth Medical Center, December 31, 2003 to present

4. Chairman, Department of Neurology, Case Western Reserve University, MetroHealth Medical Center, January 2003 to Present

5. Interim Chairman, Department of Neurology, MetroHealth Medical Center, July 1997 to January 2003

6. Adjunct Staff, Department of Neurology, Cleveland Clinic Foundation, July 1997 to present.

4/15/2023 1

Curriculum Vitae

7. Associate Staff, Department of Neurology, Cleveland Clinic Foundation, January 1995 to July 1997.

8. Clinical Associate, Department of Neurology, Cleveland Clinic Foundation, July 1994 to December 1994.

9. Neurointensive Care Fellow, Cleveland Clinic Foundation, January 1994 to March 1995.

10. Cerebrovascular Disease Fellow, Cleveland Clinic Foundation, July 1992 to July 1993.

11. Chief Resident, Department of Neurology, Case Western Reserve University School of Medicine, 1991 to 1992.

12. Resident, Department of Neurology, Case Western Reserve University School of Medicine, 1989 to 1991.

13. Resident, Department of Medicine, Cleveland Metropolitan General Hospital, 1988 to 1989.

14. Research and Development Engineer, Firestone Rubber Company, 1984.

CERTIFICATION:1. American Board of Psychiatry & Neurology, in Neurology - 1993 to

Present.2. American Board of Psychiatry & Neurology, in Vascular Neurology –

2006 to 2016

LICENSURE:1988 Ohio #592021995 DEA #BH4515043

EDUCATION:1. The Ohio State University, 2001-2003, Master of Business

Administration

2. University of Cincinnati School of Medicine, a. 1984-1988, Medical Doctor.b. Selected Honors - Alpha Omega Alpha (Honor Medical Society)

3. Case Institute of Technology, a. 1979-1984, Bachelor of Science Biomedical Engineeringb. Selected Honors - Tau Beta Pi (Honors Engineering

Society), Summa Cum Laude

PROFESSIONAL SOCIETIES:4/15/2023 2

Curriculum Vitae

1. American Academy of Neurology, 1990 to present2. Stroke Council, American Heart Association, 1993 to present3. National Stroke Association, 1994 to present4. Society of Critical Care Medicine, 1996 to 19985. Ohio State Medical Association, 1988 to 19966. American Medical Association, 1988 to 19967. Cleveland Academy of Medicine, 1988 to 19968. Fellow, American Stroke Association, 2004 to present

COMMITTEES:MetroHealth Medical Center

Hospital Operations Council, 2011 to present

Market Development Governance Committee, 2009 to 2014Board of Trustees Finance Committee, 2005 to 2014Credentials and Steering Committee, 2005 to present Medical Executive Committee, 1996 to presentMedical Education Committee, 1996 to 2000

National Quality Forum Steering Committee, Washington, D.C.:“National Voluntary Consensus Standards for the Prevention and Management of Stroke Across the Continuum of Care” Project, April 2008 to present

Board of Trustees:American Heart Association, 2015 to present (President Cleveland

Division)Northeast Ohio Stroke Association, 1997 to 2007American Heart Association, Cleveland Division, 1998 to 2001Northeast Ohio Chapter of Huntington Disease Society of America, 2002 to 2004

Department of Neurology (Cleveland Clinic Foundation) – Cerebrovascular Subcommittee, 1993 to 1996.

American Heart Association, Northeast Ohio Affiliate: 1. Stroke Council Liaison 2. Education Committee, 1994 to present 3. Chairperson, 1995 Stroke Awareness Program 4. Chairperson, 1997 Stroke Awareness Program

Cleveland Health NetworkStroke Consortium Executive CommitteeOperation Stroke, 2000Committee on Appointments, Promotion and Tenure, 2000The Academy of Medicine, ClevelandTrauma and Emergency Care Committee

5. Chairman, Ohio Department of Health-Council on Stroke Prevention &Education, Acute Stroke Pathway

4/15/2023 3

Curriculum Vitae

6. Clinical Director, Operation Stroke Executive Committee, 2001 to 2010

RESEARCH AND FUNDING

Site Principal Investigator, MetroHealth System. STROKENET – Case Western Reserve University. http://www.ninds.nih.gov/research/clinical_research/NIH_StrokeNet_Centers.htm2014 – present. Site Principal Investigator. BIOGEN 1013K201 - A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Parallel-Group Study to Evaluate the Safety and Efficacy of Intravenous Natalizumab (BG00002) on Reducing Infarct Volume in Acute Ischemic Stroke. 1/6/14 to present.

Site Principal Investigator. UCB 1394 - A Randomized, Open-label, Multicenter, Parallel-Group, Exploratory Study to Evaluate the Efficacy of IC Brivaracetam and IV Phenytoin in non-convulsive electrographic seizures. 12/18/13 to present.

Site Principal Investigator. SARA (Self-abrading Rapidly Applied) Electrode study – Phase II. Cleveland Medical Systems. 9/7/13 to present.

Site Principal Investigator. Protocol B01-02; Double-Blind, Randomized, Placebo-Controlled Phase 2 Safety and Efficacy Trial of MultiStem in Adults With Ischemic Stroke; Athersys Inc.; 2013 to present.

Site Principal Investigator. Platelet-Oriented Inhibition in New TIA and minor ischemic stroke (POINT) Trial; NIH U01NS062835; 2011 to present.

Site Principal Investigator. Insulin Resistance Intervention after Stroke (IRIS); NIH UO1NS044876; 2005 to present.

Site Principal Investigator. Warfarin vs. Aspirin in Reduced Cardiac Ejection Fraction (WARCEF); NIH-U01NS 39143, U01NS 43975; 2002 to 2013.

Site Principal Investigator. Protocol #A0081096; Prospective Randomized 12-Week Controlled Study of Visual Field Change in Subjects With Partial Seizures Receiving Pregabalin or Placebo (PFIZER-PREGABALIN); Pfizer; 2009 to 2013.

Site Principal Investigator. Secondary Prevention of Small Subcortical Stokes (SPS3); NINDS NS38529; 2003 to 2012.

Site Principal Investigator. Protocol #MP-124-A01; A Phase I, Double-Blinded, Placebo-Controlled, Ascending-Dose, Clinical Study Investigating the Safety, Tolerability, and Pharmacokinetics of MP-124 in Acute Ischemic Stoke Patients (MP-124-A01); Mitsubishi Tanabe Pharmaceuticals; 2008 to 2011.4/15/2023 4

Curriculum Vitae

Site Principal Investigator. Protocol #12649A; A Randomized Double Blind Parallel Group Placebo Controlled Phase III Study to Evaluate the Efficacy and Safety of Desmoteplase in Subjects with Acute Ischemic Stroke (DIAS 4); H. Lundbeck A/S; 2010 to 2011.

Site Principal Investigator. Protocol #01373; Membrane Activated Chelator Stroke Intervention – A Double Blind, Randomized, Placebo-Controlled, Parallel Group, Multicenter Phase III Pivotal Study to Assess the Safety and Efficacy of 1mg/kg/day Intravenous DP-b99 Over Four Consecutive Days versus Placebo When Initiated within Nine Hours of Acute Ischemic Stroke Onset (MACSI); D-Pharm Ltd.; 2010 to 2011.

Site Principal Investigator. Protocol #EFC10295; A Multicenter, Randomized, Double-Blind, Assessor-Blind, Non-Inferiority Study Comparing the Efficacy and Safety of Once-Weekly Subcutaneous Biotinylated Idraparinux (SSR126517E) With Oral Adjusted-Dose Warfarin in the Prevention of Stroke & Systemic Thromboembolic Events in Patients With Atrial Fibrillation (Borealis AF); Sanofi-Aventis; 2008 to 2010.

Site Principal Investigator. Protocol #EFC5826; Comprehensive Rimonabant Evaluation Study of Cardiovascular Endpoints and Outcomes (CRESCENDO); Sanofi-Aventis US Inc.; 2006 to 2010.

Site Principal Investigator. Siblings with Ischemic Stroke Study (SWISS); USPHS NIH NINDS NS-39987; 2000 to 2010.

Site Principal Investigator. Protocol Avail Registry; Adherence Evaluation after Ischemic Stroke Longitudinal Registry (AVAIL); Bristol Myers Squibb; 2007 to 2009.

Site Principal Investigator. Protocol #TS011-US104; A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Ascending-Dose Study of the Safety, Pharmacokinetics, and Pharmacodynamics of a Single, One-Hour Infusion of TS-011 in Acute Ischemic Stroke (AIS) Patients (TS-011); Taisho Pharmaceutical; 2006 to 2008.

Site Principal Investigator. Protocol #ONO-2506PO; A Double-Blinded, Phase II, Safety and Efficacy Evaluation of ONO-2506PO in Patients With Mild to Moderate Alzheimer’s Disease (ONO Alzheimer’s); ONO Pharma US Inc.; 2004 to 2007.

Site Principal Investigator. Protocol #9.159; A Double-Blind, Active and Placebo-Controlled Study of Aggrenox® vs. Clopidogrel + Aspirin, With and Without Micardis® (PROFESS- Prevention Regimen for Effectively Avoiding Second Strokes); Boehringer Ingelheim Pharmaceuticals, Inc.; 2004 to 2007.

4/15/2023 5

Curriculum Vitae

Site Investigator. Protocol # SA-NXY-0007; A Double-Blind, Randomized, Placebo- Controlled, Parallel Group, Multicenter, Phase IIB/III Study to Assess the Efficacy and Safety of Intravenous NXY.059 in Acute Ischemic Stroke; SAINT II (Stroke Acute Ischemic-NXY Treatment); AstraZeneca; 2004 to 2007.

Site Principal Investigator. Protocol # EFC4505; Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management and Avoidance (CHARISMA); Sanofi-Synthelabo; 2003 to 2006.

Site Principal Investigator. Protocol #SGS742-CL02; A Multi-Center, Randomized, Double-Blinded, Placebo-Controlled, Phase II Study of Efficacy and Safety of SGS742 in Subjects with Mild to Moderate Alzheimer’s Disease (SGS742 in Alzheimer’s); Saegis Pharmaceuticals; 2004 to 2006.

Site Principal Investigator. Protocol #248.543; Comparing Fixed Doses of 0.25mg, 0.50mg, and 0.75mg Pramipexole Administered Orally to Investigate the Safety and Efficacy in Patients with Idiopathic Restless Leg Syndrome for 12 Weeks (MIRIPEX); Boehringer Ingelheim; 2004 to 2006.

Site Principal Investigator. Protocol #SA-NXY-0012; A Double Blind, Randomized, Placebo Controlled, Parallel Group, Multicenter, Phase IIB Study to Assess the Safety and Tolerability of Intravenous NXY-059 in Adult Patients With Acute Intracerebral Hemorrhage (ICH) SA-NXY-0012 (CHANT); AstraZeneca; 2004 to 2006.

Site Principal Investigator. Protocol # 2506/INT0104; A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Effects of ONO-2506 Intravenous Infusion on the Amelioration of Neurology Damage and Improvement of Stroke Assessment Scale Scores in Patients with Acute Ischemic Stroke (REACT-ONO); Ono Pharma USA, Inc.; 2002 to 2006.

Site Principal Investigator. Stroke Outcomes and Neuroimaging of Intracranial Atherosclerosis (SONIA), RO1 N536643-01A1; 2000 to 2005.

Site Principal Investigator. Protocol #100282; A Randomized, Double-Blind, Placebo-Controlled Trail to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic/ Pharmacodynamic Effects of a Targeted Exposure of Intravenous Repinotan in Patients with Acute Ischemic Stroke Modified RECT (BAYER); Bayer Corporation; 2003 to 2005.

Site Principal Investigator. Protocol #FA-506-3003; A Single Rising Dose Study of FK506 Lipid Complex (LCG) in Patients with Recent Ischemic Stroke; Fujisawa Research Institute of America, Inc.; 2002 to 2005.

Site Principal Investigator. Vitamin Intervention for Stroke Prevention (VISP); USPHS NIH NINDS NS-34447; 1998 to 2004.

4/15/2023 6

Curriculum Vitae

Site Principal Investigator. Warfarin vs. Aspirin for Symptomatic Intracranial Disease (WASID), RO1 N536643-01A1; 1999 to 2004.

Site Principal Investigator. Protocol #RPCEOOA1 201 (Study NO1030); Keppra Epilepsy Evaluation of Patient Time to Response...A Phase IV, Open-Label, Multi-Center Community-Based Trial Studying the Safety and Efficacy of Levetiracetam as Add-on Therapy in Adult Patients with Treatment-Resistant, Partial-Onset Epilepsy (KEEPER); UCB Pharma, Inc.; 2000 to 2003.

Site Principal Investigator. Protocol #CAPSS-116; An Open-Label, Multicenter Trial to Evaluate the Effect of Concomitant Anti-Epileptic Drugs (AEDS) on the Tolerability of Topamax (topiramate) in Subjects with Partial Epilepsy; (TACTICS Topamax: Action of Co-therapy on Tolerability in the Clinical Setting); 2001 to 2002.

Site Principal Investigator. Protocol #SR25990C; Management of Atherothrombosis with Clopidogrel in High-Risk Patients with Recent Transient Ischemic Attack or Ischemic Stroke: A Randomized Double-Blind Study with 18 Months of Follow-Up (MATCH); Sanofi~Synthelabo; 2001 to 2002.

Site Principal Investigator. Protocol #872-CL-004; A Multicenter, Stratified, Randomized, Double-Blind Placebo-Controlled Study to Evaluate Neurologic Function and Disability in Patients with Acute Ischemic Stroke given Tissue Plasminogen Activator Plus YM872 or Tissue Plasminogen Activator Plus Placebo (ARTIST +); Yamanouchi USA Inc.; 2001 to 2002.

Site Principal Investigator. Warfarin-Aspirin Recurrent Stroke Study (WARSS); RO1 NS28371-08; 1996 to 2001.

Site Principal Investigator. Protocol #SB 214857/030; Blockade of the GP IIB/IIIA Receptor to Avoid Vascular Occlusion (BRAVO); SmithKline Beecham Pharmaceuticals; 1998 to 2001.

Site Principal Investigator. Protocol #872-CL-003; A Randomized, Double-Blind, Placebo-Controlled Study to evaluate effects of YM872 on Lesion Volume as measured by Diffusion, Perfusion and Flair Magnetic Resonance Imaging in patients with acute Ischemic Stroke (ARTIST MRI); Yamanouchi USA Inc.; 2000 to 2001.

Site Principal Investigator. Protocol #CN123-010-203; A Double-Blinded, Placebo-Controlled, Safety, Efficacy and Dose Response Trial of Two Intravenous Doses of BMS-204352 in Patients with Acute Stroke; Bristol-Myers Squibb Pharmaceutical Research Institute; 1999 to 2001.

Site Principal Investigator. Protocol #ARG-251; A Randomized, Placebo-Controlled, Three Treatment Arm Study to Study & Efficacy of Argatroban

4/15/2023 7

Curriculum Vitae

in Patients With Acute Ischemic Stroke (ARG-251); Texas Biotechnology; 04/03/2001 to 12/31/2001. Site Principal Investigator. Protocol #IP302-018; The Effects of 2000 mg Citicoline on Clinical Outcome and the Evolution of Lesion Volume in Human Stroke; Interneuron Pharmaceuticals Inc.; 1998 to 1999.

Site Principal Investigator. Protocol #GLY3002; “Gain Americas” the Safety, Efficacy and Pharmacoeconomics of an 800mg Loading Dose and Five 200mg Maintenance Doses of GV150526 in the Treatment of Patients With a Clinical Diagnosis of Acute Stroke (GAIN AMERICAS); Glaxo Welcome; 1998 to 1999.

PUBLICATIONS: PEER REVIEWEDBhatt DL. Fox KA, Hacke W, et al. for the CHARISMA Investigators. Clopidogrel

andAspirin versus Aspirin Alone for the Prevention of Atherothrombotic Events.

NEJM 2006;354.

Kasner S, Chimowitz M, Lynn M, et al. for the Warfarin Aspirin Symptomatic Intracranial

Disease (WASID) Trial Investigators. Predictors of ischemic stroke in the territory of a

symptomatic intracranial arterial stenosis. Circulation 2006; 113:555-563.

Chimowitz MI, Lynn MJ, Howlett-Smith H, et al. Comparison of warfarin and aspirin for

symptomatic intracranial arterial stenosis. N Engl J Med 2005; 352:1305-16.

Diener HC, Bogousslavsky J, Brass LM, et al. Aspirin and clopidogrel compared with

clopidogrel alone after recent ischaemic stroke or transient ischemic attack in high-risk

patients (MATCH): randomised, double-blind placebo-controlled trial. Lancet 2004; 364:

331-337.

Toole JF, Malinow, MR, Chambles LE, et al. Lowering homocysteine in patients with

ischemic stroke to prevent recurrent stroke, myocardial infarction and death. JAMA.

2004;291)565-575.

Aslanyan S, Fazekas F, Weir CJ, et al..Effect of blood pressure during the acute period of

ischemic stroke on stroke outcome – a tertiary analysis of the GAIN International Trial.

4/15/2023 8

Curriculum Vitae

Stroke 2003;34:2420-2425.

The Warfarin Aspirin Symptomatic Intracranial Disease (WASID) Trial Investigators.

Design, Progress and Challenges of a Double Blind Trial of Warfarin versus Aspirin for

Symptomatic Intracranial Arterial Stenosis. Neuroepidemiology 2003; 22:106-117

Katzan IL. Cleveland Clinic Foundation, Cleveland, OH; Sundarajan SR, Case Western Reserve University, Cleveland, OH; Furlan AJ, Cleveland Clinic Fdn. Cleveland OH; Graber TM, Southwest General Hospital, Clevalnd OH; Hanna JP, MetroHealth Medical Center, Cleveland OH; Dirosa A, American Heart Association, Northeastern Ohio Affiliate, Cleveland, OH; House G, The Stroke Group, Englewood, CO; Suarez JI, Landis DM, Case Western Reserve University, Cleveland, OH. Cuyahoga County Operation Stroke; Speed of Emergency Department Evaluation and Compliance with NINDS Time Targets. Stroke Journal of the American Heart Association, January 2002; 33:130

Seemant Chaturvedi, Detroit, MI, Bethany Lane, Michael Lynn, Barney Stern, Marc I. Chimowitz, Atlanta, GA and the WASID Study Group. (Prevalence and Treatment of Hypertension in Black and White Patients with Symptomatic Intracranial Atherosclerosis.) NEUROLOGY 2002 58, (S3).

Kyprianou A, Hanna J, Mullen K. Focal Neurological Signs in Cirrhotic Patients with Episodes of Hepatic Encephalopathy. American Journal of Gastroenterology 2001,96:273-4.

Sacco RL, DeRosa JG, Haley, Jr EC, Levin B, Ordronneau P, Phillips SJ, Rndek T, Snipes RG, Thompson JLP for the GAIN Americas Investigators. Glycine Antagonist in Neuroprotection for Patients With Acute Stroke: GAIN Americans: A Randomized Controlled Trial. JAMA 2001, 285:1719-1728.

Spence JD, Howard VJ, Chambless LE, Malinow MR, Pettigrew LC, Stampfer M, Toole JF. Vitamin Intervention for Stroke Prevention (VISP) Trial: Rationale and Design. Neuroepidemiology 2001, 20:16-25.

Hanna, J., Stroke Types. Stroke Source newsletter. September 2001, 1:1.

Sacco RL, DeRosa JT, Haley (Jr) EC, Levin B, Ordronneau P, Phillips SJ, Rundek T, Snipes RG, Thompson JLP (GAIN Americas Investigators). Glycine Antagonist in Neuroprotection for Patients With Acute Stroke. JAMA 2001, 285:13:1719-1728.

4/15/2023 9

Curriculum Vitae

Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE (Citicoline Stroke Study Group). A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001, 57:1595-1602.

Kase CS, Furlan AJ, Wechsler LR, Higashida RT, Rowley HA, Hart RG, Molinari GF, Frederick LS, Roberts HC, Gebel JM, Sila CA, Schulz GA, Roberts RS, Tech M, Gent M,PROACT II InvestigatorsC. Cerebral Hemorrhage After Intra-Arterial Thrombolysis for Ischemic Stroke. The PROACT II trial. Neurology 2001; 57:1603-1610.

Mohr JP, Thompson JLP, Lazar RM, Levin B, Sacco RL, Furie KL, Istler JP, Albers GW, Pettigrew LC, Adams HP, Jackson CM, Pullicino P (WARSS Study Group). Comparison of Warfarin and Aspirin in the Prevention of Recurrent Ischemic Stroke. New England Journal of Medicine 2001, 1444-1451, Nov 2001. Clark WM, Wechsler LR, Sabounjian LA, Schwiderski UE (Citicoline Stroke Study Group). A phase III randomized efficacy trial of 2000 mg citicoline in acute ischemic stroke patients. Neurology 2001; 57:1595-1602.

Damore DT, Ramundo ML, Hanna JP, Dayan PS. Parental Attitudes toward BB and Pellet Guns. Clinical Pediatrics (Phila) 2000 May; 39(5):281-4.

Benesch C, Chimowitz MI, for the WASID investigators: Best treatment for intracranial arterial stenosis? 50 years of uncertainty. Neurology 2000; 55:465-6.

McCreary M, Emmerman C, Hanna JP, Simon J. Acute myelopathy following intranasal insufflation of heroin: A case report. Neurology 2000 July; 55(2):316-17.

Bekavac I, Hanna JP, Sila C. Warfarin and Low-Dose Aspirin for Stroke Prevention From Severe Intracranial Stenosis. J of Stroke and Cerebrovascular Diseases. 1999, 8(1): 33-37; Editorial Commentary by Robert G. Hart, 8(1): 33-37.

Furlan A, Higashida R, Wechsler L, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in Acute cerebral Thromboembolism. JAMA 1999, 282:2003-2011.

Hanna JP and Ramundo ML. Rhabdomyolysis and hypoxia associated with prolonged propofol infusion in children. Neurology 1998, 50(1):301-303.

del Zoppo GJ, Higashida RT, Furlan AG, et al. PROACT: A phase II randomized trial of pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT Investigators. Prolyse in Acute Cerebral Thromboembolism. Stroke 1998, 29:4-11.

4/15/2023 10

Curriculum Vitae

Bekavac I, Hanna JP, Wallace RC, Powers J, Ratliff NB, Furlan AJ. Thrombolysis for Embolic Stroke in a Patient with Atrial Myxoma. Neurology 1997, 49(8): 618-20.

Sun JP, Stewart WJ, Hanna JP, and Thomas JD. TEE Diagnosis of Patent Foramen Ovale by Contrast and Color Doppler: Relationship to Left Atrial Size. American Heart Journal 1996, 131(2): 239-244.

Hanna JP, Frank JI, Furlan AJ, and Sila CA. Predicting Depressed Consciousness from Hemispheric Infarction with Edema. J of Stroke and Cerebrovascular Diseases 1996, 6(1): 1-6.

Hanna JP, Frank JI. Automatic walking in the pontomedullary phase of central herniation. Neurology 1995, 45(5): 985-6.

Hanna JP, Sun JP, Furlan AJ, Stewart WJ, Sila CA, Tan M. Patent foramen ovale and brain infarct: echocardiographic predictors, recurrence rate, and treatment. Stroke.1994, 25(4): 782-786.

Sawyer RP, Hanna JP Leigh RJ, and Ruff R. Asymmetry of forearm rolling as a sign of unilateral cerebral dysfunction. Neurology 1993, 43(8): 1596-1598.

Leigh RJ, Seidman SH, Grant MP, and Hanna JP. Loss of ipsidirectional quick phases of torsional nystagmus with a unilateral midbrain lesion. Journal of Vestibular Research 1993, 3:115-121.

Hanna JP, Schmidley JR. Datura delirium. Clinical Neuropharmacology 1992, 15(2): 109-113.

Grant MP, Leigh RJ, Seidman SH, Riley DE, Hanna JP, Comparison of predictable smooth ocular and combined eye-head tracking behavior in patients with lesions affecting the brainstem and cerebellum. Department of Neuroscience, Department of Veterans Affairs Medical Center, Cleveland Ohio. Brain 1992, 115:1323-1342.

NON PEER REVIEWEDThe Cleveland Plain Dealer Hanna JP. Gambling and Parkinson’s

disease - medications, illness, or a little of both. May 22, 2012.

The Cleveland Plain Dealer Hanna JP. Falls are a danger to seniors, but many are avoidable. July 11, 2008. Cleveland, Ohio.

The Cleveland Plain Dealer Hanna JP. Risks for stroke, a killer for seniors, can be reduced. May 9, 2008. Cleveland, Ohio. 4/15/2023 11

Curriculum Vitae

News from Metro Life Flight Hanna JP, Liskay A. Improved Outcomes Offsetby Increase Occurrence. Spring 2004 19:1: p7.

The Cleveland Plain Dealer Hanna JP. Array of Area Hospitals Offer Stroke Treatment. March 5, 2002. Cleveland, Ohio.

The Cleveland Plain Dealer, Hanna JP letters to the editor, Stroke Savior? - Drug's use debated in battle to save the brain. January 2000. Cleveland, Ohio.

Sun Newspaper's Cleveland Health Today, Hanna JP. Onslaught by stroke is preventable with work to eliminate risk factor. May 6, 1999.

Cleveland Magazine, Hanna JP. Surviving Stroke - Through a variety of physical and mental therapies, stroke sufferers are able to return to the life that they one lived. August 1998, Volume 27. Number 8.

BOOK CHAPTERSHanna JP. Multiple Sclerosis. in Loue S., Sajatovic. et al. editors., The Encyclopedia of Aging and Public Health, 1st edition New York: Springer Publishing Company. 2008

Hanna JP. Pain. in Loue S., Sajatovic. et al. editors., The Encyclopedia of Aging and Public Health, 1st edition New York: Springer Publishing Company. 2008

Hanna JP. Multiple Sclerosis. in Loue S., Sajatovic. et al. editors. , Encyclopedia of Women’s Health. Kluwer Academic/Plenum Publishers, 2004.

Hanna JP. Pain. in Loue S., Sajatovic. et al. editors. Encyclopedia of Women’s Health. Kluwer Academic/Plenum Publishers, 2004

Hanna JP and Furlan AJ. Brain Ischemia - Basic Concepts and ClinicalRelevance. Chapter 12: Cardiac Disease and Embolic Sources. Springer-Verlag, 1995; pp. 299-316.

Hanna JP and Furlan AJ. Conn's Current Therapy. Focal IschemicCerebrovascular Disease. WB Saunders Company, 1994, p.838-840.

ABSTRACTS:Hanna JP, Ruggieri PM, et al. Magnetic Resonance Angiography in the Posterior Circulation Presented - American Neurological Association for October, 1993.

Hanna JP, Stewart WJ, Furlan AJ, Sila CA. Patent Foramen Ovale & Brain Infarct Echocardiographic Predictors, Recurrence and Prevention. Presented 4/15/2023 12

Curriculum Vitae

- 19th International Joint Conference on Stroke and Cerebral Circulation, February 17-19, 1994.

The WASID Study Group. Warfarin - Aspirin Symptomatic Intracranial Disease (WASID) Study. Presented - 19th International Joint Conference on Stroke and Cerebral Circulation, February 17- 19, 1994.

Hanna JP, Frank JI, Furlan AJ, Sila CA. Predicting depressed consciousness from supratentorial non-hemorrhagic infarct mass effect. Presented National Stroke Association Annual Meeting, Denver, Colo., June, 1995.

Sun JP, Stewart WJ, Hanna JP, and Thomas JD. TEE Diagnosis of Patent Foramen Ovale by Contrast and Color Doppler: Relationship to Left Atrial Size. Presented -American College of Cardiology 43rd Annual Scientific Session 1995.

Rensel MR, Frank J, Masaryk T, Sila C, Wallace R, Furlan A, Chyatte D, Hanna JP. Current Management of Symptomatic Vertebrobasilar Stenosis. 48th Annual American Academy of Neurology, March 27, 1996, San Francisco, CA.

Bekavac I, Hanna J. Thrombolysis for Embolic Stroke in a Patient with Atrial Myxoma. Presented - 1st Croatian World Congress of Anesthesiology, Intensive Care and Emergency Medicine, September 1996, Hvar, Croatia.

Hanna J, Ramundo M. Rhabdomyolysis during Maintenance Infusion of Propofol for the Treatment of Refractory Status Epilepticus in Children. Presented - American Academy of Neurology, 49th Annual Meeting, April 15, 1997, Boston, MA.

Bekavac I, Hanna J, Sila C. Warfarin and Low-Dose Aspirin for Stroke Prevention in Patients with Severe Large Arterial Intracranial Stenosis Failing Monotherapy. Presented - American Academy of Neurology, 49th Annual Meeting, April 17, 1997, Boston, MA.

Logan K, Furlan A, Hanna J, Walz E. Prosthetic Heart Valves, Anticoagulation and Hematomas. American Academy of Neurology 50th Annual Meeting, Minneapolis, MN, April 25-May 2, 1998.

Bekavac I, Seti P, Wong O, Hanna J. Utilizing Stress Technitium-99m-ECD Brain SPECT in the Management of Intracranial Stenosis. American Academy of Neurology 50th Annual Meeting, Minneapolis, MN, April 25-May 2, 1998.

Wierzbicki TJ, Hanna, J. Posttraumatic Cerebral Infarction: A Trauma Center Cohort Study. American Academy of Neurology – 52nd Annual Meeting, San Diego, CA, April 29-May 6, 2000.

Leonard C, Pirozzi M, Liskay A, Hanna, J. Pilot Study Assessing the Effectiveness of Stroke Prevention Education in Spanish vs. English in 4/15/2023 13

Curriculum Vitae

Hispanics. J Stroke and Cerebrovascular Disease J Stroke and Cerebrovascular Diseases. 9:(4) 202. 2000. The Warfarin-Aspirin Recurrent Stroke Study (WARSS): Initial Results – The WARSS Clinical Trial Group.26th International Stroke Conference, Ft. Lauderdale, FL, February 14-16, 2001.

The Warfarin-Aspirin Recurrent Stroke Study (WARSS): Initial Result – Contemporary Clinical Issues Plenary Session. 53rd American Academy of Neurology Annual Meeting. Philadelphia, PA, May 5-11, 2001.

Liskay A, Manoharan V, Thakore N, Winkelman M, Hanna J. Quality and Changes after Creating an Acute Stroke Unit. Stroke Pathway. San Frncisco, California 2001.

Katzan IL, Sundararajan SR, Furlan AJ, et al. Cuyahoga County Operation Stroke Speed of Emergency Department Evaluation and Compliance with NINDS Time Targets. 27th International Stroke Conference. February 7-9, 2002. San Antionio, Texas.

Mohr JP, Sciacca RR, Thompson JLP, et al. Aspirin Failure in the Warfarin Aspirin Stroke Study. 28th International Stroke Conference. February 13-15, 2003. Phoenix, Arizona.

LaMonte MP for the ARGIS-I Investigators. Results of ARGIS-I: Argatroban Injection in Acute Ischemic Stroke. 28th International Stroke Conference. February 13-15, 2003. Phoenix, Arizona.

Fisher M, Bozik ME, et al. 90-day Outcome of Patients Receiving I.I. tPA in the POST Trials. 28th International Stroke Conference. February 13-15, 2003. Phoenix, Arizona.

The Paul Coverdell Pilot Registry Investigators. Paul Coverdell National Acute Stroke Registry: Refinement of Data Elements for Pilor Implementation of Prototypes. 28th International Stroke Conference. February 13-15, 2003. Phoenix, Arizona.

Pettigrew LC, Kasner SE, Kwiatkowski T, et al. Safety and Tolerability of ONO-2506 in Acute Ischemic Stroke. 29th International Stroke Conference. February 4-6, 2004. San Diego, California.

Chimowitz M, Lynn M, Howlett-Smith H, et al. Warfarin-Aspirin Symptomatic Intracranial Disease (WASID) Trial: Trial Results. 29th International Stroke Conference. February 4-6, 2004. San Diego, California.

Hague S, Brown WM, Rih SS, et al Absence of Linkage of the STRK1 Locus to Ischemic Stroke in the North American Population : The SWISS Study. 29th International Stroke Conference. February 4-6, 2004. San Diego, California.4/15/2023 14

Curriculum Vitae

Beck JC, Beiswanger CM, Meschia JF, et al. Creating a Permanent Genetic resource for Studies of Ischemic Stroke: The SWISS Study. 29th International Stroke Conference. February 4-6, 2004. San Diego, California.

Pettigrew LC, Kasner SE, Gorman M, et al. ONO-2506 Suppresses S-100B in Ischemic Stroke Patients. 29th International Stroke Conference. February 4-6, 2004. San Diego, California.

Meschia JF, Brott TG, Hardy J, et al. Susceptibility to Ischemic Stroke Subtype May Noy Be Genetically Determined: The SWISS Study. 29th International Stroke Conference. February 4-6, 2004. San Diego, California.

LOCAL LECTURES:1. "Depression Following Stroke". St. Alexis Hospital, March 18,

1993.

2. "Rehabilitation Following Stroke". Cleveland Stroke Club, June 16, 1993.

3. "Stroke - Types, Causes, Prevention, Treatment & Recovery". Byzantine Socialites, August 11, 1993.

4. "The Behavioral Manifestations of Focal Cerebrovascular Disease". Teaching Series, Department of Neurology, Cleveland Clinic Foundation.

5. "Stroke - Causes, Prevention, and Treatment". OASIS Group, December 12, 1993.

6. "Stroke - Rehabilitation/Exercise". American Heart Association/East Suburban Stroke Club. April 6, 1994.

7. "Stroke - Warning Signs and Prevention". Cleveland Stroke Club, Cleveland Heights, Ohio. September 21, 1994.

8. "Neurology of Walking". Grand Rounds, Department of Neurology, Cleveland Clinic Foundation, February 1, 1995.

9. "Stroke: Early Prevention and Management". Emergency Medicine - New

Developments, Cleveland Clinic Foundation, February 16, 1995.

10. “CNS Imaging for Acute Stroke”. General Internal Medicine Grand Rounds, Cleveland Clinic Foundation, April 17, 1996.

11. “Are You at Risk for Stroke?” Women’s Health Perspectives, Cleveland Clinic Foundation, May 18, 1996.

4/15/2023 15

Curriculum Vitae

12. “Hyperacute Therapy For Ischemic Cerebrovascular Disease”. Medicine Grand Rounds, MetroHealth Center, Cleveland, Ohio, November 27, 1996.

13. “Aneurysmal Subarachnoid Hemorrhage” Neurology Update, Cleveland, OH, March 1, 1997.

14. “Antibodies in Stroke” Neurology Update, Cleveland, OH, March 2, 1997.

15. “Stroke Awareness” AHA, Radio Interview/Q104, Cleveland, OH, May 1, 1997.

16. “Mechanisms of Stroke” John Hay High School, Cleveland Clinic Teaching Series, Cleveland, OH, May 2, 1997.

17. “Stroke Awareness” AHA Lecture, Cleveland State University School of Nursing, Cleveland, OH, May 13, 1997.

18. “Stroke & TIA” Internal Medicine Lecture Series, MetroHealth Medical Center, Cleveland, OH, August 20, 1997.

19. "Stroke, Headache, & Neurovascular Disease in Pregnancy" Perinatal Physiology, and Pathology Clinical Impressions, MetroHealth Medical Center, Cleveland, OH, December 8, 1998.

20. "Update in the Management of Stroke" Department of Family Practice Lecture Series, MetroHealth Medical Center, Cleveland, OH, January 13, 1999.

21. “Brain Attack: Minimizing Your Risks” TRW, Inc., Cleveland, OH, June 23, 1999.

22. Brain Attack: Signs, Symptoms and Treatment” Department of Pharmacy, MetroHealth Medical Center, Cleveland, OH, July 19, 1999.

23. "Seizures and Status Epilepticus" Nuts and Bolts Series, 1999, Department of Medicine, MetroHealth Medical Center, Cleveland, OH, August 6, 1999.

24. “TIA/CVA" Nuts and Bolts Series, 1999, Department of Medicine, Medical Center, Cleveland, OH, August 25, 1999.

25. “Brain Attack - Present and Future" Parma Community General Hospital, Parma, OH, September 15, 1999.

4/15/2023 16

Curriculum Vitae

26. New Directions in Stroke Prevention and Treatment" St. Charles Mercy Hospital, Oregon, OH, September 17, 1999.

27. "Epidemiology, Risk Factors and Prevention" and "Acute Management and Diagnostics" Resident Didactic Series, Department of Physical Medicine and Rehabilitation, Stroke Rehabilitation. MetroHealth Medical Center, Cleveland, OH, October 1999.

28. "Antiplatelet" Dinner presentation, Bristol Myers Squibb Company, Cleveland, OH, October 1999.

29. "Update on Brain Attack" Geriatric Conference, Deaconess Hospital, Cleveland, OH, November 1999.

30. Neuroscience Grand Rounds, University Hospitals of Cleveland, Cleveland, OH, January 21, 2000.

31. “Brain Attack – First Response” CME lecture to Life Flight nurses, MetroHealth Medical Center, Cleveland, OH, February 2000.

32. "Take Wellness to Heart" The Health Museum of Cleveland, sponsored by The American Heart Association, Cleveland, Ohio, February 2000.

33. "Stroke Prevention in the New Millenium" Summit County Medical Society/Akron General Hospital, Akron, OH, March 2000.

34. “Brain Attack” Department of Surgery, MetroHealth Medical Center, Cleveland, OH, March 2000.

35. "Stroke Prevention and Treatment" for Living Well with MetroHealth, Brooklyn Branch, Cuyahoga County Library, Cleveland, OH, March 2000.

36. “Neurologic Localizing” Emergency medicine resident lecture, MetroHealth Medical Center, Cleveland, OH, April 2000.

37. “Advancement of Antiplatelet Therapy for the Prevention of Atherosclerotic Events” Talk sponsored by Sanofi-Synthelabo, Boardman, OH, August 2000.

38. “Secondary Stroke Prevention and the role of Aggrenox” sponsored by Boehringer Ingleheim Pharmaceuticals, Inc., Youngstown, Ohio, September 2000.

39. “Advancements of Antiplatelet Therapy for the Prevention of Atherosclerotic Events” sponsored by Sanofi Pharmaceuticals, Chagrin Falls, OH, September 2000.

4/15/2023 17

Curriculum Vitae

40. “Stroke Dilemma” Recognition-Rx-Regionalization/2ndAnnual Stroke Symposium sponsored by at Summa Health System, Akron, OH, October 2000.

41. “TIA and Stroke” Geriatric Conference sponsored by Bristol Myers Squibb/Boehringer Ingelheim Pharmaceuticals, Deaconess Hospital, Cleveland, OH, October 2000.

42. “Stroke in the New Millenium” sponsored by Boehringer Ingleheim Pharmaceuticals, Allen Memorial Hospital, Oberlin, OH, March 2001.

43. “Current Treatment of Stroke and TIA’s” sponsored by Boehringer Ingleheim Pharmaceuticals and Bristol-Myers Squibb Company, St. Vincent Charity Hospital, Cleveland, OH, March 2001.

44. Primary Care Track (PCT) lecture. Physical Diagnosis Instruction. Case Western Reserve University, Cleveland, OH, March 2001.

45. “Antiplatelet Therapy for Ischemic Stroke” sponsored by Boehringer Ingleheim Pharmaceuticals, Pelee Island, Ontario, Canada, August 2001.

46. “Cerebral Vascular Accident” sponsored by Boehringer Ingleheim Pharmaceuticals. Medical College of Ohio and The Bellevue Hospital, Port Clinton, OH, October 2001.

47. “Headache Primary Care Tutorial” Lecture Internal Medicine, MetroHealth Medical Center, Cleveland, OH, May 22, 2002

48. “Antiplatelet Therapy of Stroke Prevention” PM&R Grand Rounds MetroHealth Medical Center, Cleveland, OH, May 23, 2002.

49. “Coronary Heart Disease and Stroke” Lecture The Mended Hearts Inc. (affiliated with the American Heart Association,) MetroHealth Medical Center, Cleveland, OH, June 12, 2002

50. “Stroke, Headache and Neurovascular Disease in Pregnancy” Perinatal and Pathology Series, Division of Child Neurology, MetroHealth Medical Center Cleveland, OH, October 16, 2002.

51. “Status Epilepticus” Pulmonary Medicine Noon Conference Series, MetroHealth Medical Center, Cleveland, OH, May 8, 2003.

52. “The Brain and Its Functions” Out Reach Program, Chippewa Elementary School, Brecksville, OH, May 20, 2003.

4/15/2023 18

Curriculum Vitae

53. “Cranial Nerves – Anatomy and Clinical Correlation” Oral Surgery Teaching Series, MetroHealth Medical Center, Cleveland, OH. August 5, 2003.

54. “Stroke Care: What is on the Horizon?” Northeast Ohio Stroke Association Annual Meeting, Independence, OH, October 16, 2003.

55. “Imaging Modalities for Common Psychiatric Syndromes” Psychiatry Grand Rounds MetroHealth Medical Center, Cleveland, OH, November 13, 2003.

56. “Stroke: Nuts and Bolts” MetroHealth Medical Center, Cleveland, OH, November 28, 2003.

57. “Stroke Prevention - 2004” Boehringer-Ingelheim Pharmaceuticals Inc., Lockkeeper’s Inn, Independence, OH, January 20, 2004.

58. “Women and Stroke” Neurology Grand Rounds, MetroHealth Medical Center, Cleveland, OH, March 2004.

59. “Top 10 Stroke Studies of 2003” Neurology Grand Rounds, MetroHealth Medical Center, Cleveland, OH, May 2004.

60. “Women & Stroke” American Heart Association Operation Stroke Nursing Seminar, Independence, OH, May 26, 2004.

61. “Stroke Update – 2004” Deaconess Health Fair, Deaconess-Krafft Center, Cleveland, OH, May 27, 2004.

62. “The Brain and Its Functions” Out Reach Program, Chippewa Elementary School, Brecksville, OH, May 27, 2004.

63. “Stroke Concerning Women” Fairview Hospital, Department of Family Medicine Grand Rounds, Cleveland OH, June 2, 2004.

64. “The Cranial Nerves and Clinical Examination” Department of Maxillofacial/Reconstructive Surgery, MetroHealth Medical Center, Cleveland, OH August 24, 2005.

65. “TIA/Stroke – An Update” Department of Family Practice, MetroHealth Medical Center, Cleveland, OH, August 25, 2004.

66. “Headaches and Pregnancy – An Update” Department of Obstetrics and Gynecology, MetroHealth Medical Center, Cleveland, OH, September 1, 2004.

4/15/2023 19

Curriculum Vitae

67. “Women and Stroke” Department of Obstetrics and Gynecology Grand Rounds, MetroHealth Medical Center, Cleveland, OH, October 5, 2004.

68. “Update on Stroke” Boehringer-Ingelheim Pharmaceuticals Inc., Alberini’s Restaurant, Niles, OH, December 28, 2004.

69. “Secondary Stroke Prevention” Boehringer Ingelheim Pharmaceuticals Inc., Clarion Hotel, Independence, OH, March 3, 2005.

70. “Stroke – a Prevention Strategy for Seniors” Home Instead Senior Care, Intercontinental Hotel, Cleveland, OH, April 7, 2005.

71. “The Importance of Antiplatelet Therapy in Stroke” Sanofi Aventis & Bristol-Myers Squibb Company, Johnny’s Cleveland OH, April 13, 2005.

72. “Update on Stoke Secondary Prevention” Medical Surgical Seminar 2005, Youngstown, OH, April 15, 2005.

73. “Cognitive Changes in Aging” The Aging Brain: Normal and Not So Normal, Holiday Inn Cleveland South, Independence OH, November 10 2005.

74. “Stroke Prevention” Neurology Update, Lake Hospital System, Radisson Hotel & Conference Center, Eastlake, OH, January 26, 2006.

75. “Stroke, Headache, and Neurovascular Disease in Pregnancy”. MetroHealth Medical Center, September 11, 2007 and September 21, 2010.

76. “Management of Stroke”, Advanced Topics In Caring For the Older Adult, MetroHealth Medical Center, Cleveland, OH, November 5, 2007.

77. “Multiple Sclerosis Diagnosis”, MS Society Ohio Buckeye Chapter, Independence, OH, September 15, 2011.

78. “Emergent Assessment and Treatment of Seizures” Metro LifeFlight Lecture Series. February 4, 2013

79. MetroHealth Life Flight 31st Annual Symposium- Neuro Emergencies Panel presentation. Friday May 30, 2014

80. Cuyahoga County WIC Program 2014 – “Brain Power - How to stay mentally sharp”. June 27, 2014.

4/15/2023 20

Curriculum Vitae

81. “Carotid atherosclerotic disease – a review”. Surgical Grand Rounds, MetroHealth System. July 2014.

82. Metro Life Flight Lecture Series: EMS Advances in Stroke Care. October 6, 2014.

STATE-WIDE LECTURES:1. "Ischemic Stroke Awareness Forum". Ashtabula County Medical

Center American Heart Association, Ashtabula, Ohio, May 16, 1995.

2. "Ischemic Stroke Awareness Forum". Providence Hospital, American

Heart Association, Sandusky, Ohio, May 17, 1995.

3. "Ischemic Stroke Awareness Forum". Allen Memorial Hospital, American

Heart Association, Oberlin, Ohio, May 25, 1995.

4. “Acute Management of Ischemic Cerebrovascular Disease”. Medical Grand Rounds, Elyria, Memorial Hospital, March 20, 1997, Elyria, Ohio.

5."New Directions in Stroke Prevention and Treatment". The Mosaic of Care in the Elderly, St. Charles Mercy Hospital. September 1997. Oregon, Ohio.

6.“What Are The Signs For A Stroke? Workshop at Men’s Health, Education and Awareness Expo. June 2001. Columbus, Ohio.

7.“Stroke Prevention – Update 2006”, Neurology Update Lake Hospital System, January 25, 2006.

INTERNATIONAL LECTURES:1. “Hyperacute Treatment on Ischemic Cerebrovascular Disease”.

1st Croatian World Congress of Anesthesiology, Intensive Care and Emergency Medicine. Hvar, Croatia, September 19, 1996.

2. “Antiplatelet Therapy for Ischemic Stroke.” Sponsored by Boehringer Ingelheim Pharmaceuticals. August 2001. Pelee Island, Ontario, Canada.

MISCELLANEOUS:Ad Hoc Reviewer, NeurologyAd Hoc Reviewer, Stroke

4/15/2023 21

Curriculum Vitae

Ad Hoc Reviewer, Annals of Internal MedicineAd Hoc Reviewer, Journal of NeurosurgeryAd Hoc Reviewer, Journal of NeuroimagingAd Hoc Reviewer, HepatologyPrinciple Developer/Presenter, Multispecialty Cerebrovascular Disease Conference, Cleveland Clinic Foundation, Department of NeurologyCleveland Clinic Foundation/John Hay High School Partnership, 1993-95Master Clinician Event, Case School of Medicine, 2005

CERTIFICATIONS/AWARDS:

The Leadership Deep Dive – Weatherhead School of Business, 2011-2012. Physician Management Education Program – MetroHealth Medical Center, Spring 2000

PATENTS:Method and Apparatus for Relief of Headache, Filed: May 25, 2005 – US Patent Office

OTHER MEDIA:“Stroke Awareness”. AHA Lecture (live broadcast), Hilltop Retirement Center & WELW radio station, May 12, 1997, Cleveland, Ohio.

"Healthlines" radio program. The Academy of Medicine of Cleveland. October 20, 1998. Cleveland, Ohio.

Quoted in article, "Hospital network aims for fast, efficient care of stroke patients" in August 18, 1999 issue of The Cleveland Plain Dealer

"Healthlines" radio program. The Academy of Medicine of Cleveland. October 21, 1999. Cleveland, Ohio.

"News Today" Morning Show, Channel 3 TV. October 27, 1999. Cleveland, Ohio.

"Neurological Issues in the African American Community" - Cleveland Talk Radio. March 16, 2000. Cleveland, Ohio.

“The Cleveland Plain Dealer’, quoted in article “While stroke centers do help, you might not be taken to one.” June 2000. Cleveland Ohio.Healthlines radio program on Alzheimer’s Disease. The Academy of Medicine of Cleveland. April 12, 2001. Cleveland Ohio.

“The Cleveland Plain Dealer”, quoted in article “Array of area hospitals offer stroke treatment”. March 2002. Cleveland Ohio.

“Golden Opportunities” Channel 3 TV. July 23rd 2003. Cleveland Ohio.

4/15/2023 22

Curriculum Vitae

“Lanigan & Webster” Radio Talk Show, (Avanir Research Study) December 16, 2003. Cleveland Ohio.

“Golden Opportunities” Channel 3 TV. October 6, 2004. Cleveland Ohio.

Named in Cleveland Magazine’s “Top Docs” issue, March 2008, March 2009, March 2010, March 2011. Cleveland Ohio.

Guest Columnist for The Cleveland Plain Dealer’s Senior Health column, “Risks for Stroke, a Killer for Seniors, can be reduced”, May 2008. Cleveland Ohio.

Golden Opportunities Show #677 Laughter, Humor and the Betterment of StrokeSeptember 29, 2013.

WKYC Channel 3, Parkinson’s and Depression. August 14, 2014 www.wkyc.coom/story/news/health/2014/08/14/link-between-depression-and-parkinsons/14091985.

WEWS Channel 5, Parkinson’s and Depression. August 14, 2014. www.kjrh.com/lifestyle/health-and-fitness/robin-williams-suffered-from-early-stages-of- parkinsons-disease.

REFERENCES: upon request

4/15/2023 23